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Key messages
What is the key question? Is there a dysregulation in pulmonary and systemic 
antimicrobial peptides (AMP) associated with the frequent exacerbator phenotype in 
bronchiectasis?
What is the bottom line? Frequent exacerbators have dysregulation of AMPs with 
particularly high levels of the cathelicidin LL-37 and low levels of secretory leukocyte 
protease inhibitor (SLPI) in sputum, which could predict time to next exacerbation and 
the frequency of exacerbations during follow-up. 
Why read on? This is the first study to describe AMP dysregulation in the frequent 
exacerbator phenotype in bronchiectasis.
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ABSTRACT 
Rationale: Recently a frequent exacerbator phenotype has been described in 
bronchiectasis but the underlying biological mechanisms are unknown. Antimicrobial 
peptides (AMP) are important in host defense against microbes but can be 
proinflammatory in chronic lung disease. 
Objectives: To determine pulmonary and systemic levels of AMP and their 
relationship with disease severity and future risk of exacerbations in bronchiectasis.
Methods: A total of 135 adults with bronchiectasis were prospectively enrolled 
at three European centers. Levels of cathelicidin LL-37, lactoferrin, lysozyme and 
Secretory Leukocyte Protease Inhibitor (SLPI) in serum and sputum were determined at 
baseline by ELISA. Patients were followed-up for 12 months. We examined the ability 
of sputum AMP to predict future exacerbation risk. 
Measurements and main results: AMP levels were higher in sputum than in 
serum, suggesting local AMP release. Patients with more severe disease at baseline had 
dysregulation of airway AMP. Higher LL-37 and lower SLPI levels were associated 
with bronchiectasis severity index (BSI), lower FEV1 and Pseudomonas aeruginosa 
infection. Low SLPI levels were also associated with the exacerbation frequency at 
baseline. During follow-up, higher LL-37 and lower SLPI levels were associated with a 
shorter time to the next exacerbation, while LL-37 alone predicted exacerbation 
frequency over the next 12 months.  
Conclusions: Patients with bronchiectasis showed dysregulated sputum AMP 
levels, characterized by elevated LL-37 and reduced SLPI levels in the frequent 
exacerbator phenotype. Elevated LL-37 and reduced SLPI levels are associated with 
Pseudomonas aeruginosa infection and can predict future risk of exacerbations in 
bronchiectasis.
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INTRODUCTION
Bronchiectasis is a chronic inflammatory lung disease characterized by 
permanent dilatation of the bronchi. Most patients suffer daily cough and sputum 
production and some of them experience frequent exacerbations (1). A frequent 
exacerbator phenotype has recently been described, in which patients consistently have 
multiple exacerbations over time and this condition independently predicts worse 
clinical outcomes including increased mortality (2). The underlying biological 
mechanisms leading to frequent exacerbations in this group have not yet been identified, 
but frequent exacerbators appear to have greater neutrophilic inflammation and are 
more susceptible to infection with bacteria, particularly Pseudomonas aeruginosa (3, 4).
Antimicrobial peptides (AMP) are important in host defense against pathogenic 
microbes in the lung (5). Among the most important and abundant antimicrobial 
peptides in the airway are lysozyme, lactoferrin and the cathelicidin LL-37 (which are 
proinflammatory mediators released from activated neutrophils, macrophages and 
bronchial epithelium) and Secretory Leukocyte Protease Inhibitor (SLPI; produced by 
respiratory epithelial cells and mostly anti-inflammatory) (6, 7). AMP function through 
multiple mechanisms including protein degradation (lysozyme), nutrient depletion 
(lactoferrin), cellular disruption and lysis, and inhibition of virulence factors (LL-37, 
SLPI) (8, 9). AMP are designed to protect against bacterial infection but in the context 
of chronic lung inflammation bacteria such as P. aeruginosa adapt to resist AMP 
killing, changing methods of iron acquisition and variations in biofilm-associated 
polysaccharides (10). The result may be an ineffective and excessive AMP response that 
stimulates inflammation without achieving bacterial clearance (11). 
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A consistent finding in bronchiectasis is the persistence of bacterial infection 
despite an excessive inflammatory response which instead of achieving bacterial 
clearance results in host damage (3, 12). The contribution of AMP to the vicious cycle 
of bronchiectasis has not been previously explored. We therefore hypothesized that 
AMP are altered in sputum from patients with bronchiectasis and may correlate with 
disease severity and predict future risk of exacerbations.
METHODS
Study design and Ethics
This was an international, multicenter, prospective, observational study which 
included consecutive adults with bronchiectasis. The study protocol was approved by 
local institutional review board and all subjects gave signed informed consent.
Participants
Patients were recruited from three regional specialist bronchiectasis clinics at the 
Hospital de la Santa Creu i Sant Pau (Barcelona, Spain), Ospedale Maggiore Policlinico 
(Milano, Italy) and Ninewells Hospital (Dundee, UK).
Bronchiectasis was defined by the presence of bronchial dilatation on high-
resolution CT scanning with a compatible clinical history of cough, sputum production 
and/or recurrent respiratory infections. Patients with cystic fibrosis, primary 
immunodeficiency, active malignancy, active allergic bronchopulmonary aspergillosis, 
interstitial lung disease, active mycobacteria disease, HIV infection and long-term oral 
corticosteroid treatment were excluded. 
Clinical assessments
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All patients were clinically stable, defined by the absence of an exacerbation that 
required antibiotic treatment within 30 days. Frequent exacerbators were defined as 3 or 
more exacerbations per year at baseline. Demographic data, number of exacerbations in 
the previous year, relevant comorbid conditions and current treatments were recorded. 
Exacerbations were recorded as moderate (treated with antibiotics but not requiring 
hospitalization) or severe (requiring hospitalization or intravenous antibiotics). All 
patients underwent spirometry (13). The underlying etiology of bronchiectasis was 
determined after testing recommended by current guidelines (1, 14). The Bronchiectasis 
Severity Index (BSI) and FACED scores were calculated (15, 16). Severe disease was 
considered when BSI score was ≥ 9 points and FACED score was ≥ 5 points.
Longitudinal outcomes
Patients were followed-up for one year from the time of sputum and serum 
collection. During follow-up, patients were visited every 6 months as part of routine 
clinical practice at the study centers. Time to first exacerbation was calculated as the 
time from sampling to the first day of antibiotic administration because of an 
exacerbation. 
Bacteriology 
All bacteriology was performed on spontaneous early-morning sputum samples. 
Sputum was separated from saliva and the sample split for bacteriology and assessment 
of AMP levels. Samples were processed for bacteriology as previously described (17). 
AMP and inflammatory mediator measurement 
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Methods of sputum and blood processing were standardized across the 3 sites. 
Sputum samples were processed by ultracentrifugation at 50,000g for 90 minutes 
followed by careful extraction of the supernatant. Samples were processed within 2 
hours of expectoration and immediately frozen at -80C.
Serum and sputum Lactoferrin, Lysozyme (AssayPro, St. Charles, MO, USA), 
LL-37 (Hycult Biotech, Plymouth, PA, USA), SLPI and Matrix metallopeptidase 9 
(MMP-9) (R&D Systems, Minneapolis, MN, USA) levels were measured by validated 
commercially available ELISA kits. Sputum samples were diluted 1/25000 for 
Lactoferrin and Lysozyme, 1/20 for LL-37 and 1/2000 for SLPI assays. The limits of 
detection were 0.625 ng/ml for lactoferrin, 0.0781 ng/ml for lysozyme, 0.14 ng/ml for 
LL-37 and 0.025 ng/mL for SLPI. Neutrophil elastase activity in sputum supernatants 
was measured by activity based immunoassay (ProAxsis LTD, Belfast, UK) as 
previously described (18). 
Western Blot
To investigate the degradation of SLPI in bronchiectasis airway sputum the 
samples were subjected to denaturing gel electrophoresis on 15% SDS-PAGE gels 
before being transferred to nitrocellulose.  After blocking with 5% skimmed milk in 
PBST the membranes were incubated overnight in anti-SLPI antibody at 0.1g/ml 
(R&D cat no AF1274) at 4ºC.  After incubation with Anti-goat HRP (BioRad, Watford 
(UK) cat no 1721034) at 1/2500 dilution for 1 hour the blot was washed thoroughly in 
PBST before SLPI proteins were visualized using Millipore Immobilon Western 
Chemiluminescent HRP substrate (cat no WBKLS0100) used as per manufacturers 
recommendation. A representative autoradiographic film is shown.
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Air-liquid interface nasal epithelial cell culture
Nasal basal epithelial cells obtained from healthy and bronchiectasis patients 
were grown and seeded into 24-well transwell inserts at p2 or p3. Cells were fully 
differentiated into ciliated air-liquid interface cultures using Pneumocult ALI+ media 
(Stemcell technologies, Cambridge UK). Cells were apically treated with 100µl/well of 
PBS (control), Neutrophil Elastase at 3µg/ml (Sigma, Elastase from human leukocyte, 
E8140-1UN), with or without elastase inhibitor (AstraZeneca, AZD9668) at 10nM (a 
dose sufficient to completely block elastase activity as determined in preliminary 
experiments) or inhibitor alone. After 30mins of incubation at 37OC, apical supernatants 
were collected. An additional 100µl/well PBS used to wash the apical surface of the 
cells and added to the corresponding supernatants. Baseline characteristics of healthy 
controls are described in the Methods section of the online data supplement.  
Statistical analysis
 Statistical analysis was performed using SPSS version 22. Categorical variables 
are presented as frequencies and percentages and comparisons performed using χ2 or 
Fisher exact test when required. Continuous variables are presented as mean and 
standard deviation (SD) in parametrical variables and median and interquartile range 
(IQR) in non-parametrical ones. Differences were analysed using Student t-test, 
ANOVA test or their corresponding non-parametrical test when required (Kruskal-
Wallis and Mann-Whitney tests). The relationship between linear variables was studied 
using linear regression and Spearman rank correlation (rho and p-value), with the latter 
included because relationships between inflammatory biomarkers were not assumed to 
be linear. Data are reported with the rho and p-values derived from the Spearman rank 
correlation. The contribution of different proteases to SLPI levels was studied with 
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multiple linear regression. Exacerbation rate was analyzed using a negative binomial 
model with time in study as an offset. Time to first exacerbation was modeled using 
Cox’s proportional hazard regression. Exacerbation rate and time to first exacerbation 
were adjusted for BSI, site and fully adjusted for bronchiectasis severity, gender, 
aetiology, inhaled corticosteroid use and site. Patients lost to follow-up or dying within 
the 1 year follow-up were censored in the analysis. Discrimination between groups for 
prediction of hospitalization for severe exacerbations was tested using the area under the 
receiver operator characteristic curve. A p value <0.05 was considered significant. 
RESULTS
Patient characteristics
A total of 135 adults with stable bronchiectasis were included in the study. 
Table 1 shows the baseline characteristics of the population. Mean age was 69 (±10) 
years and 56% were females. The majority of patients had idiopathic or post-infective 
bronchiectasis and the mean BSI score was 8.0 (±4.3) and FACED score was 2.4 (±1.5), 
indicating moderate to severe bronchiectasis. Most of the patients (65%) were receiving 
inhaled long-acting bronchodilator treatment, whereas 43% were receiving inhaled 
corticosteroid treatment and 4% were receiving inhaled antibiotics. 322 exacerbations 
were recorded in the previous year, including 32 (10%) that require hospitalization. 68 
patients (50.4%) were frequent exacerbators defined as 3 or more exacerbations per year 
at baseline. Frequent exacerbators had worse lung function and more severe disease 
compared to non-frequent exacerbators (see online table E1).
AMP levels in sputum and blood
Page 10 of 42
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
11
All measured AMP in patients with bronchiectasis were higher in sputum than in 
serum. Lactoferrin was the AMP with highest pulmonary expression, with a median 
(IQR) of 114.6 (45.7-250.6) µg/ml. In serum, lactoferrin levels were 4.3 (2.3-6.5) 
µg/ml. Lysozyme was the AMP with highest systemic expression with a median (IQR) 
of 5.8 (4.4-7.3) µg/ml. In sputum, lysozyme levels were 68.9 (42.1-105.2) µg/ml. LL-37 
levels were 1444 (28.1-8054) ng/ml in sputum and 328.3 (204.3-533.1) ng/ml in serum 
while SLPI levels were 536.4 (161.7-2729) ng/ml in sputum and 120.8 (85.6-152.2) 
ng/ml in serum. 
No correlations between pulmonary and systemic AMP levels were found. 
Spearman rank correlation between sputum and serum lactoferrin was rho=-0.05 
(p=0.59), between sputum and serum lysozyme was rho=0.06 (p=0.49), between 
sputum and serum LL-37 was rho=0.08 (p=0.36), and between sputum and serum SLPI 
was rho=0.03 (p=0.73).
AMP levels and disease severity
Patients with severe disease had elevated LL-37 levels and lower SLPI levels. 
Using the BSI score, the highest sputum LL-37 levels were detected in patients with 
severe BSI score in comparison to patients with moderate and mild disease (3835 (56.9-
13502) vs 108.2 (21.1-6456) vs 148.7 (17.3-2743) ng/ml, p=0.007). Sputum SLPI levels 
were the lowest in the most severe group in comparison to moderate and mild patients 
(341.6 (88.8-1635) vs 608.5 (275.9-2678) vs 875.5 (444.1-7415) ng/ml, p=0.004) 
(Figure 1). Using the FACED score, similar relationships were observed to those seen 
with BSI although overall group differences were not statistically significant (p=0.05 
and p=0.1 respectively, see online Figure E1). No correlation among systemic AMP 
levels and disease severity were found.
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A weak inverse significant correlation was also observed between sputum LL-37 
(rho=-0.25, p=0.004), lactoferrin (rho=-0.23, p=0.006) and lysozyme (rho=-0.19, 
p=0.02) with FEV1, whereas sputum levels of SLPI had a weak correlation (rho=0.17, 
p=0.05) (see online Figure E2). No correlations between serum determinations and lung 
function tests were observed.
Frequent exacerbators had significant lower airway SLPI compared to infrequent 
and non-exacerbators (350.2 (101.7-2583) vs 560.7 (269.2-2424) vs 934.3 (385.1-7206) 
ng/ml, p=0.01). Sputum lysozyme, lactoferrin and LL-37 were not associated with 
baseline exacerbation frequency (see online Figure E3). Systemic AMP levels were not 
associated with exacerbation frequency.
AMP levels and airway infection
Sputum cultures were positive for bacteria in 86 patients (64%) and negative in 
49 (36%). P. aeruginosa was the most frequently isolated pathogen in sputum culture 
(n=39, 29%), followed by Haemophilus influenzae (n=31, 23%), Staphylococcus aureus 
(n=6, 4%), Escherichia coli (n=3, 2%), Moraxella catharralis (n=2, 1%), 
Stenotrophomona (n=2, 1%), Streptococcus pneumoniae (n=2, 1%) and Serratia 
marcensens (n=1, 0.7%). Clinical characteristics of patients grouped according to the 
presence of P.aeruginosa, other pathogens or negative sputum culture (who were 
considered non-infected) are showed online (see online Table E2). 
When compared to patients infected by other pathogens and non-infected 
patients, bronchiectasis patients with P.aeruginosa showed significantly higher sputum 
LL-37 levels (3835 (72.2-12435) vs 2425 (36.2-9658) vs 57.8 (17.1-3651) ng/ml, 
p=0.002), higher sputum lactoferrin levels (190.7 (68.1-364.3) vs 99.2 (40.4-250.6) vs 
79.3 (45.7-201.1) ng/ml, p=0.04), and lower sputum SLPI levels (363.3 (103.7-739.7) 
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vs 753.3 (161.7-2624) vs 1066 (309.5-6245) ng/ml, p=0.001) (Figure 2). No differences 
in systemic AMP levels were found between patients infected by P.aeruginosa, patients 
infected by other pathogens and non-infected patients.
No differences in sputum AMP levels were found when patients with and 
without chronic macrolide treatment and inhaled corticosteroids were compared In 
addition, no differences were found among patients with and without nebulized 
antibiotics, although the small proportion of treated patients (n=6, 4%) did not exclude a 
potentially effect (see online table E3). 
AMP and Elastase activity
A significant correlation between sputum LL-37 (rho=0.36, p=0.002), sputum 
lactoferrin (rho=0.38, p<0.001), sputum lysozyme (rho=0.26, p=0.03) and elastase 
activity were found (see online Figure E4). A previous study identified that in cystic 
fibrosis SLPI was degraded by neutrophil elastase into lower molecular weight cleavage 
products (19), while a further study found degradation by MMP-9 (20). We 
hypothesized that proteases activity in the bronchiectasis airway would be responsible 
for lower levels of SLPI. We found, however, no significant correlation between SLPI 
and elastase activity (rho=-0.09, p=0.46) or MMP-9 (rho=-0.13, p=0.2) (Figure 3A and 
3B). In multiple linear regression incorporating elastase activity and MMP-9, proteases 
accounted for a maximum of 23% of the variance in SLPI levels. 
By western blot, we identified a heterogeneous pattern of SLPI cleavage with no 
association between neutrophil elastase activity and SLPI cleavage pattern (Figure 3C). 
Based on previous work that suggest neutrophil elastase can prevent release of 
SLPI from lung epithelial cells (21) we tested whether exogenous neutrophil elastase 
inhibited SLPI secretion from primary airway epithelial cells. We observed that nasal 
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epithelial cells from controls and bronchiectasis secreted similar amounts of SLPI 
(301.6 (167.4-676.4) vs 163.1 (128.8-340.4), p=0.46) (Figure 3D). The addition of 
exogenous elastase decreased the secretion of SLPI to 21.6 (13.8-37.7)% of the 
secretion from cells treated with control buffer (p=0.03). The NE inhibitor alone had no 
significant impact on SLPI release, while the addition of NE and inhibitor still resulted 
in inhibition of SLPI release suggesting that this effect was independent of NE protease 
activity (p=0.028) (Figure 3E).
Longitudinal outcomes
132 out of 135 patients (98%) completed 12 months of follow-up. During this 
time, a total of 310 exacerbations have been recorded in 102 patients, including 36 
severe exacerbations. The median number of exacerbations per patient was 2.0. In 
univariate analysis, patients with 3 or more exacerbations during follow-up had higher 
levels of LL-37 (2976 (48.8-15472) vs 416.4 (21.8-7251) vs 61.4 (19.8-2865) ng/ml, 
p=0.02) and lower levels of SLPI (316.3 (89.9-944.1) vs 753.3 (343.1-3914) vs 1261 
(265.2-6521) ng/ml, p<0.001) in comparison to those patients with 1 or 2 exacerbations 
and patients without exacerbations (Figure 4).
In an exploratory analysis we examined outcomes for patients above and below 
a cut-off representing the median of the population (to the nearest whole number). 
Patients with LL-37 1500 ng/ml had a higher frequency of exacerbations (Incidence 
Rate Ratio (IRR) 1.57, 95%CI 1.04-2.37, p=0.02). Patients also had a shorter time to 
next exacerbation with LL-37 levels above the median for the population (Hazard Ratio 
(HR) 1.68, 95%CI 1.13-2.50, p=0.01). These findings persisted after adjusting for BSI 
and site (see table E4 in the online data supplement). LL-37 showed an area under the 
curve (AUC) of 0.76 (0.65-0.86), p<0.0001 for predicting hospitalization (see online 
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Figure E5). 
For SLPI, low levels were not significantly associated with a higher frequency of 
exacerbations (IRR 0.76, 95%CI 0.50-1.51, p=0.1) but did demonstrate a shorter time to 
next exacerbation when a cut-off of 1000 ng/ml was used (HR 0.63, 95%CI 0.42-0.94, 
p=0.02) (Figure 4). After adjusting for BSI and site, a trend to predict the time to first 
exacerbation was observed (see online table E4). SLPI showed an AUC of 0.74 (0.62-
0.86), p<0.0001 for predicting hospitalization for severe exacerbation (see online Figure 
E5). 
DISCUSSION
This study demonstrates that airway AMP, especially high LL-37 and low SLPI 
sputum levels are associated with disease severity, disease activity and airway infection 
in patients with bronchiectasis. In addition, patients with higher levels of LL-37 and 
lower levels of SLPI had a shorter time to the next exacerbation and an increase 
frequency of exacerbations during follow-up. The relationships between LL-37/SLPI 
and both prior and future exacerbations suggest that dysregulation of AMP may be one 
of the mechanisms underlying the frequent exacerbator phenotype in bronchiectasis. 
Our findings suggested that AMP may be ineffective as an innate host defense 
mechanism, especially in those bronchiectasis patients with severe disease and with 
chronic P. aeruginosa infection. This fact may contribute to maintaining a vicious cycle 
of increased inflammation without eliminating bacterial infection. If further validated in 
prospective larger studies, LL-37 and SLPI could represent novel biomarkers to predict 
future risk of exacerbations in patients with bronchiectasis.
AMP are important in host defense against bacteria, viruses and fungi (5).  They 
are produced by respiratory epithelial cells, neutrophils and macrophages and play an 
Page 15 of 42
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
16
important role in innate lung defense (6, 8). Although no previous comprehensive 
studies of AMP in bronchiectasis have been conducted, our results complement and 
extend previous observations in other chronic airway diseases such as Chronic 
Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). In COPD, increased 
sputum levels of LL-37 were associated with airflow limitation, health status and 
exercise tolerance (22), and lower sputum lysozyme and SLPI levels were detected in 
patients with bacterial colonization and during acute infectious exacerbations (23). In 
bronchiectasis, one previous study demonstrated that high levels of sputum LL-37 were 
detected in patients chronically infected with P. aeruginosa (24). In our study, we 
demonstrated that elevated sputum LL-37 and reduced sputum SLPI levels were 
associated with disease severity, worse lung function and the presence of airway 
infection, especially due to P. aeruginosa. In addition, sputum lactoferrin and lysozyme 
levels were also associated to worse lung function and sputum SLPI were lower in 
frequent exacerbators. Local production of AMP in the lung, probably related to chronic 
airway inflammation, is likely to be the key mechanism in bronchiectasis, since we 
observed much higher levels in sputum than in serum and no relationship between 
serum levels and disease severity. 
LL-37 is a human cathelicidin produced by neutrophils and epithelial cells in 
response to pro-inflammatory stimuli including cytokines, pathogen-associated 
molecular patterns and tissue injury (25). LL-37 displays antimicrobial activity against 
Gram-positive and Gram-negative bacteria, fungi and viruses, neutralizes LPS activity, 
and protects against endotoxic shock  (26). In addition, it is involved in the regulation of 
inflammation, cell proliferation and apoptosis (27). In our study, we demonstrated that 
high pulmonary levels of LL-37 are associated to disease severity, worse lung function 
and airway infection. It may seem contradictory that the presence of airway infection 
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and exacerbation risk is associated with higher levels of an AMP that should reduce 
infection. However, previous studies primarily in CF have demonstrated that the 
interaction of LL-37 with DNA and with glycosaminoglycan in the inflamed lung 
impairs the antibacterial function of LL-37 and its ability to neutralize LPS (28, 29). 
LL-37 is therefore able to enhance mucus production and promote inflammation while 
losing its antimicrobial activity (30). These previous findings likely explain the high 
levels of LL-37 identified in our study and how LL-37 may contribute to poor 
outcomes. 
Bacterial clearance is the primary function of AMP. However, some pathogens, 
especially P. aeruginosa, have developed different process of adaptation to innate 
immune clearance mechanisms in the lung, such as creation of biofilms, resistance to 
inflammasome-mediated clearance and resistance to AMP (11). A recent study 
evaluating P. aeruginosa populations using whole-genome sequencing in patients with 
bronchiectasis showed that P. aeruginosa populations adapt by accumulating loss-of-
functions mutations. This fact leads to changes in phenotypes including different modes 
of iron acquisition and variations in biofilm-associated polysaccharides (10). These 
findings may explain why, despite an appropriate host response increasing AMP 
secretion, P. aeruginosa persists in the lungs and the elevated AMP levels could 
contribute to perpetuate an excessive inflammatory response, impacting negatively on 
clinical outcomes.
In contrast to the LL-37 data, in our study sputum levels of SLPI were lower in 
the most severe patients and in those infected by P. aeruginosa. The main function of 
SLPI is to protect local tissue from the detrimental consequences of inflammation, as a 
result of its anti-protease activity and anti-inflammatory properties (7, 31). Previous 
studies have demonstrated decreased levels of SLPI in patients with CF infected with P. 
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aeruginosa due to neutrophil elastase degradation (19).  In keeping with the emerging 
data that CF and bronchiectasis have highly diverging pathophysiology we found a 
different relationship in bronchiectasis. SLPI levels were not related to sputum 
neutrophil elastase activity or MMP-9 levels. SLPI degradation was heterogeneous with 
multiple cleavage products and was unrelated to elastase activity in sputum. Most 
patients, even those with high levels of SLPI by ELISA, had evidence of SLPI 
degradation suggesting that functional SLPI deficiency may be present even in patients 
with preserved protein levels. Our data suggest that multiple proteases such as matrix 
metalloproteinases and cathepsins are likely contributing to SLPI deficiency in the 
airway. However, protease levels only accounted for a maximum of 23% of the variance 
in sputum SLPI levels, suggesting an important contribution from reduced SLPI 
production. In addition, our data demonstrates that elastase reduces release of SLPI 
from epithelial cells independent of its protease activity, as previous data suggested 
(21). Other studies have generated a variant of SLPI resistant to degradation by 
neutrophil elastase (32). However, our data has important therapeutic implications since 
neutrophil elastase inhibitors that are in development for the treatment of bronchiectasis 
would not be expected to restore normal SLPI function in view of our findings. 
Our study has limitations. First, this study was exploring multiple biomarkers 
and so we acknowledge the risk of spurious associations as a result of multiple 
statistical comparisons. We addressed this, however, by looking at baseline data with 
multiple markers and then focusing our prospective follow-up study on LL-37 and SLPI 
only, markers which had shown a clear association with disease severity at baseline. 
The finding of consistent results during follow-up makes spurious associations very 
unlikely. Our results were consistent, biologically plausible and robust across all studied 
AMP..  Second, the absence of a control group prevents the comparison of AMP levels 
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of bronchiectasis patients and healthy subjects. And finally, although our study is the 
largest of AMP in bronchiectasis, using well characterized patients in multicenter and 
international study, it is not possible to clarify if dysregulated AMP levels are markers 
of disease severity more than a cause of exacerbation, and further studies are needed to 
better clarify this point. Our study did not explore how sputum biomarkers could be 
implemented into clinical practice, which may be limited because of the need for 
sputum processing.  
In conclusion, we found that patients with bronchiectasis show dysregulated 
AMP characterized by elevated pro-inflammatory LL-37, lactoferrin and lysozyme with 
reduced anti-inflammatory SLPI. The frequent exacerbator phenotype is associated with 
increased levels of LL-37 and degradation of SLPI, providing the first biological 
characterization of this key phenotype. 
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Table 1.  Patient demographics, clinical characteristics and prior treatments.
Patients (n = 135)
Age (mean ± SD) 69.1 (10.5)
Male 59 (43.7)
Smoking status
         Never 82 (60.7)
         Ex-smoker 23 (17.0)
         Current 30 (22.2)
Comorbidities
         Cardiovascular disease 32 (23.7)
         Diabetes mellitus 13 (9.6)
         Stroke
Treatment
          Inhaled bronchodilators
          Inhaled corticosteroids
          Inhaled antibiotics
          Chronic macrolide therapy 
12 (8.9)
88 (65.2)
59 (43.7)
6 (4.4)
31 (23.0)
FEV1 (% pred) (mean ± SD) 78.3 (28.3)
FVC (% pred) (mean ± SD) 94.3 (27.0)
BMI (kg/m2) (mean ± SD) 25.9 (5.6)
Aetiology
         Idiopathic 61 (45.2)
         Post-infective 22 (16.3)
         Post-tuberculosis
         COPD
         Rheumatoid arthritis
         CTD
         ABPA
         Primary Ciliary dyskinesia
         Inflammatory bowel disease
         Asthma
          Haematological malignancy    
associated  immunodeficiency
         Young syndrome
         Specific antibody deficiency
12 (8.9)
12 (8.9)
6 (4.4)
4 (3.0)
4 (3.0)
3 (2.2)
3 (2.2)
3 (2.2)
2 (1.5)
2 (1.5)
1 (0.7)
Exacerbations previous 12 months
         0 24 (17.8)
         1 28 (20.7)
         2 
         3
         4 or more
15 (11.1)
20 (14.8)
48 (35.6)
BSI (mean ± SD)
FACED ( mean ± SD)
8.0 (4.3)
2.4 (1.5)
Data is expressed by number (%) as otherwise is indicated. FEV1: Forced Expiratory 
Volume in 1 second; FVC: Forced Vital Capacity; BMI: Body Mass Index; COPD: 
Chronic Obstructive Pulmonary Disease. CTD: Connective Tissue Diseases; ABPA:  
allergic bronchopulmonary aspergillosis BSI: Bronchiectasis Severity Index
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FIGURE LEGENDS
Figure 1.-Association of sputum AMP levels and severity of disease. A: Sputum LL-37 
levels and BSI score divided in mild (0-4 points), moderate (4-8 points) and severe (9 or 
more points), B: Sputum SLPI levels and BSI score divided in mild, moderate and 
severe. p values are obtained by Kruskal-Wallis test. Graphs are represented as mean 
and SEM.
Figure 2.- Sputum AMP levels (A: LL-37, B: SLPI, C: lactoferrin, and D: lysozyme) 
and the presence of airway infection. Patients are divided in non-infected, infected by 
other pathogens different than P. aeruginosa and infected by P. aeruginosa. p values 
are obtained by Kruskal-Wallis test. Graphs are represented as mean and SEM
Figure 3.-A: Relationship between sputum SLPI and neutrophil elastase activity. B: 
Relationship between sputum SLPI and sputum MMP-9 levels. Rho and p-value were 
obtained from Spearman rank correlation, while the dotted line is derived from linear 
regression. C: Western Blot demonstrating degradation pattern of SLPI in sputum. Each 
column represents an individual patient ordered from left to right in terms of increasing 
sputum neutrophil elastase activity (measured by immunoassay as described in the 
methods). Abbreviations (NE: Neutrophil Elastase, FL SLPI= full length secretory 
leukocyte protease inhibitor, CP1= cleavage product 1, CP2= cleavage product 2, CP3= 
cleavage product 3). D: SLPI secretion from nasal epithelial cells of control and 
bronchiectasis patients. E: SLPI secretion from control (CON1 and CON2) and 
bronchiectasis (BE) nasal epithelial cells untreated (control buffer) or treated with 
Elastase, Inhibitor or a mixture of Elastase and inhibitor.
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Figure 4.- A: Sputum SLPI levels and Frequency of exacerbations during 1 year follow 
up. B: Time to next exacerbation. Percentage of patients free of exacerbation using LL-
37 1500 ng/ml as a cut-off (Hazard Ratio (HR) 1.68 (95%CI 1.13-2.50, p=0.01). C: 
Sputum SLPI levels and Frequency of exacerbations during 1 year follow up. D: Time 
to next exacerbation. Percentage of patients free of exacerbation using SLPI 1000 ng/ml 
as a cut-off (HR 0.63 95%CI 0.42-0.94, p=0.02). p values in panel A and C are obtained 
by Kruskal-Wallis test. Graphs are represented as mean and SEM.
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Figure 1.-Association of sputum AMP levels and severity of disease. A: Sputum LL-37 levels and BSI score 
divided in mild (0-4 points), moderate (4-8 points) and severe (9 or more points), B: Sputum SLPI levels 
and BSI score divided in mild, moderate and severe. p values are obtained by Kruskal-Wallis test. Graphs 
are represented as mean and SEM. 
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Figure 2.- Sputum AMP levels (A: LL-37, B: SLPI, C: lactoferrin, and D: lysozyme) and the presence of 
airway infection. Patients are divided in non-infected, infected by other pathogens different than P. 
aeruginosa and infected by P. aeruginosa. p values are obtained by Kruskal-Wallis test. Graphs are 
represented as mean and SEM 
338x190mm (300 x 300 DPI) 
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Figure 3.-A: Relationship between sputum SLPI and neutrophil elastase activity. B: Relationship between 
sputum SLPI and sputum MMP-9 levels. Rho and p-value were obtained from Spearman rank correlation, 
while the dotted line is derived from linear regression. C: Western Blot demonstrating degradation pattern of 
SLPI in sputum. Each column represents an individual patient ordered from left to right in terms of 
increasing sputum neutrophil elastase activity (measured by immunoassay as described in the methods). 
Abbreviations (NE: Neutrophil Elastase, FL SLPI= full length secretory leukocyte protease inhibitor, CP1= 
cleavage product 1, CP2= cleavage product 2, CP3= cleavage product 3). D: SLPI secretion from nasal 
epithelial cells of control and bronchiectasis patients. E: SLPI secretion from control (CON1 and CON2) and 
bronchiectasis (BE) nasal epithelial cells untreated (control buffer) or treated with Elastase, Inhibitor or a 
mixture of Elastase and inhibitor. 
338x190mm (300 x 300 DPI) 
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Figure 4.- A: Sputum SLPI levels and Frequency of exacerbations during 1 year follow up. B: Time to next 
exacerbation. Percentage of patients free of exacerbation using LL-37 1500 ng/ml as a cut-off (Hazard Ratio 
(HR) 1.68 (95%CI 1.13-2.50, p=0.01). C: Sputum SLPI levels and Frequency of exacerbations during 1 year 
follow up. D: Time to next exacerbation. Percentage of patients free of exacerbation using SLPI 1000 ng/ml 
as a cut-off (HR 0.63 95%CI 0.42-0.94, p=0.02). p values in panel A and C are obtained by Kruskal-Wallis 
test. Graphs are represented as mean and SEM. 
338x190mm (300 x 300 DPI) 
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Antimicrobial peptides, disease severity and exacerbations in Bronchiectasis 
 
Oriol Sibila, Lídia Perea, Elisabet Cantó, Amelia Shoemark, Diane Cassidy, Alexandra Smith, 
Guillermo Suarez-Cuartin, Ana Rodrigo-Troyano, Holly R Keir, Martina Oriano, Samantha Ong, 
Silvia Vidal,  Francesco Blasi, Stefano Aliberti, James D Chalmers. 
 
 
ONLINE DATA SUPPLEMENT 
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METHODS 
Air-liquid interface nasal epithelial cell culture 
For the nasal cilia stuff, healthy controls were recruited from NHS Tayside and University of Dundee 
staff aged 25 to 60 years old. All controls had no history of rhinitis, asthma or other respiratory disease 
and were required to be free of upper respiratory tract infection for at least 6 weeks prior to nasal 
sampling. 
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RESULTS 
AMP levels and FACED score 
High sputum LL-37 levels were detected in patient with severe FACED score (7633 (719.1-
21135) vs 2678 (30.1-9056) vs 329.6 (21.8-6412) ng/ml, p=0.05) while sputum SLPI levels were 
the lowest in the most severe group (236.2 (84.7-901.5) vs 769.7 (125.7-3592) vs 637.4 (296.0-
3812) ng/ml, p=0.1) (Figure E1).  
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Table E1. Patient demographics, clinical characteristics and prior treatments among non-
frequent exacerbators and frequent exacerbators.  
 Non-frequent 
exacerbators (n = 67) 
Frequent exacerbators 
(n = 68) 
P value 
Age (mean ± SD) 69.3 (±10.6) 68.7 (±10.5) 0.3 
Male 32 (54.2) 27 (45.8) 0.3 
Smoking status    
         Never 44 (65.7) 38 (55.9) 0.1 
         Ex-smoker 13 (19.4) 10 (14.7)  
         Current 10 (14.9) 20 (29.4)  
Comorbidities 
         Cardiovascular disease 
 
14 (20.9) 
 
18 (26.5) 
 
0.4 
         Diabetes mellitus 6 (9.0) 7 (10.3) 0.8 
          Stroke 
Treatment 
          Inhaled long-acting bronchodilator 
          Inhaled corticosteroids 
          Inhaled antibiotics 
          Chronic macrolide therapy  
5 (7.5) 
 
35 (52.2) 
24 (35.8) 
2 (4.0) 
17 (25.4) 
7 (10.3) 
 
53 (77.9) 
35 (59.3) 
4 (7.0) 
14 (20.6) 
0.6 
 
0.002 
0.07 
0.5 
0.5 
FEV1 (% pred) (mean ± SD) 87.5 (±27.7) 69.3 (±26.2) <0.0001 
FVC (% pred) (mean ± SD) 101.6 (±26.1) 87.1 (±26.2) 0.004 
BMI (kg/m2) (mean ± SD) 26.4 (±4.4) 25.4 (±6.5) 0.06 
Aetiology    
         Idiopathic 33 (49.3) 28 (41.2) 0.1 
         Post-infective 12 (17.9) 10 (14.7)  
         Post-TBC 8 (11.9) 4 (5.9)  
         Others 14 (20.9) 26 (38.2)  
Exacerbations previous 12 months    
         0 24 (35.8) 0 (0.0) <0.0001 
         1 28 (41.8) 0 (0.0)  
         2  
         3 
         4 or more 
15 (22.4) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
20 (29.4) 
48 (70.6) 
 
BSI (mean ± SD) 
FACED ( mean ± SD) 
5.8 (±3.0) 
2.1 (±1.4) 
10.3 (±4.3) 
2.6 (±1.7) 
<0.0001 
0.1 
 
Data are presented as n(%) unless otherwise indicated. 
BMI, body mass index; BSI, Bronchiectasis Severity Index; FEV1, forced expiratory volume in 
1 s; FVC, forced vital capacity; PPB, potentially pathogenic bacteria; TBC, tuberculosis; SD, 
standard deviation. 
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Table E2. Patient demographics, clinical characteristics and prior treatments among non-
infected, infected by P. aeruginosa and infected by other pathogens 
 
Non-infected  
(n = 49) 
Infected by 
other pathogens  
(n = 47) 
Infected by 
P. aeruginosa 
 (n = 39) 
P value 
Age (mean ± SD) 67.8 (10.6) 70.9 (10.6) 68.7 (10.3) 0.4 
Male 17 (34.7) 24 (51.1) 18 (46.2) 0.3 
Smoking status     
         Never 31 (63.3) 24 (51.1) 27 (69.2) 0.2 
         Ex-smoker 9 (18.4) 7 (14.9) 7 (17.9)  
         Current 9 (18.4) 16 (34.0) 5 (12.8)  
Comorbidities 
         Cardiovascular disease 
 
10 (20.4) 
 
11 (23.4) 
 
11 (28.2) 
 
0.7 
         Diabetes mellitus 6 (12.2) 6 (12.8) 1 (2.6) 0.2 
         Stroke 4 (8.2) 4 (8.5) 4 (10.3) 0.9 
Treatment 
          Long-acting bronchodilator 
          Inhaled corticosteroids 
          Inhaled antibiotics 
          Chronic macrolide therapy 
 
28 (57.1) 
15 (30.6) 
0 (0) 
12 (24.5) 
 
27 (57.4) 
24 (51.1) 
4 (8.5) 
9 (19.1) 
 
34 (85) 
20 (51.3) 
2 (5) 
10 (25.6) 
 
0.01 
0.07 
0.1 
0.7 
FEV1 (% pred) (mean ± SD)     85.5 (23.5)         83.6 (29.3)         62.8 (27.3) <0.001 
FVC (% pred) (mean ± SD) 98.1 (23.7) 99.7 (26.2) 83.1 (29.2) 0.008 
BMI (kg/m2) (mean ± SD) 26.3 (5.6) 27.6 (5.7) 23.3 (4.2) 0.001 
Bronchiectasis etiology     
      Idiopathic 16 (32.7) 29 (61.7) 16 (41.0) 0.1 
      Post-infective 9 (18.4) 6 (12.8) 7 (17.9)  
      Post-tuberculosis 6 (12.2) 1 (2.1) 5 (12.8)  
      Others 18 (36.7) 11 (23.4) 11 (28.2)  
Exacerbations previous 12 months     
         0 13 (26.5) 9 (19.1) 2 (5.1) 0.1 
         1 13 (26.5) 8 (17.0) 7 (17.9)  
         2  
         3 
         4 or more 
5 (10.2) 
8 (16.3) 
10 (20.4) 
4 (8.5) 
6 (12.8) 
20 (42.6) 
6 (15.4) 
6 (15.4) 
18 (46.2) 
 
BSI (mean ± SD) 
FACED (mean ± SD) 
5.7 (3.2) 
1.7 (1.2) 
7.7 (3.8) 
1.9 (1.1) 
11.5 (4.0) 
3.73 (1.4) 
<0.001 
<0.001 
Data are presented as n(%) unless otherwise indicated. 
BMI, body mass index; BSI, Bronchiectasis Severity Index; FEV1, forced expiratory volume in 1 s; 
FVC, forced vital capacity; PPB, potentially pathogenic bacteria; SD, standard deviation. 
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Table E3.- Sputum LL-37, SLPI, lactoferrin and lysozyme levels in bronchiectasis patients with 
and without inhaled antibiotic treatment, chronic macrolide therapy and inhaled corticosteroids 
treatment. 
 No chronic macrolides  
n=104 (77%) 
Chronic macrolides  
n= 31 (27%) 
p-value 
Sputum LL-37 (ng/ml) 2440.4 (18.4-7422.1) 26.0 (11.4-10667.6) 0.3 
Sputum SLPI (ng/ml) 535.2 (191.6-2610.3) 637.4 (89.9-4042.3) 0.6 
Sputum Lactoferrin (µg/ml) 118.5 (50.2-248.3) 55.7 (37.0-300.4) 0.2 
Sputum Lysozyme (µg/ml) 69.2 (42.1-106.0) 63.7 (37.2-95.2) 0.7 
 
 No ICS 
n=76 (56%) 
ICS 
n= 59 (44%) 
p-value 
Sputum LL-37 (ng/ml) 1986.3 (17.6-6074.7) 361.9 (12.1-12334.0) 0.6 
Sputum SLPI (ng/ml) 659.0 (173.4-4220.4) 509.9 (129.0-2569.0) 0.5 
Sputum Lactoferrin (µg/ml) 117.5 (49.5-239.8) 113.5 (40.39-285.0) 0.7 
Sputum Lysozyme (µg/ml) 68.4 (37.5-103.0) 75.6 (42.5-106.2) 0.9 
 
 No inhaled antibiotic 
n= 129 (96%) 
Inhaled antibiotic 
n=6 (4%) 
p-value 
Sputum LL-37 (ng/ml) 1443.7 (17.0-8108.1) 2654.7 (29.2-9348.6) 0.3 
Sputum SLPI (ng/ml) 560.7 (178.5-3534.5) 246.1 (94.7-861.2) 0.8 
Sputum Lactoferrin (µg/ml) 114.6 (46.1-246.0) 136.9 (43.3-385.5) 0.6 
Sputum Lysozyme (µg/ml) 69.5 (42.3-105.6) 41.6 (19.1-114.4) 0.5 
Data are presented as median (Interquartile range). ICS: Inhaled corticosteroids 
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Table E4.- Analysis of negative binomial model with adjustments. 
 
  Effect 
estimate 
95% CI p-value 
LL-37 ≥1500 ng/ml  IRR   
Exacerbation Rate Unadjusted 1.57 1.04-2.37 0.02 
 Adjusted for BSI 1.53 1.01-2.31 0.04 
 Adjusted for site 1.52 1.01-2.28 0.04 
 Fully adjusted 1.51 0.97-2.34 0.068 
  HR   
Time to first exacerbation  Unadjusted 1.68 1.13-2.50 0.01 
 Adjusted for BSI 1.58 1.05-2.36 0.02 
 Adjusted for site 1.68 1.11-2.56 0.01 
 Fully adjusted 1.72 1.12-2.64 0.01 
SLPI <1000 ng/ml  IRR   
Exacerbation Rate Unadjusted 0.76 0.50-1.15 0.1 
 Adjusted for BSI 0.77 0.50- 1.17 0.2 
 Adjusted for site 0.73 0.48- 1.11 0.1 
 Fully adjusted 0.63 0.39-0.98 0.04 
  HR   
Time to first exacerbation Unadjusted 0.63 0.42-0.94 0.02 
 Adjusted for BSI 0.68 0.45-1.03 0.06 
 Adjusted for site 0.70 0.46-1.05 0.08 
 Fully adjusted 0.65 0.41-1.02 0.059 
 
Fully adjusted includes adjustment for bronchiectasis severity, gender, aetiology, inhaled corticosteroid 
use and site.  
IRR= incidence rate ratio, HR= hazard ratio, BSI=Bronchiectasis Severity Index 
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FIGURE LEGENDS 
Figure E1. A: Sputum LL-37 levels of FACED score, divided as mild (0-2 points), moderate (2-
4 points) and severe (5-7 points), and B: Sputum SLPI levels of FACED score. p values are 
obtained by Kruskal-Wallis test. Graphs are represented as mean with SEM.   
Figure E2. Relationship between sputum AMP levels (A: LL-37, B: lysozyme, C: lactoferrin 
and D: SLPI) and FEV1% predicted. Rho and p-value were obtained from Spearman rank 
correlation. 
Figure E3. A: Sputum LL-37 and B: SLPI levels and frequency of exacerbations in the previous 
year. p values are obtained by Kruskal-Wallis test. Graphs are represented as mean with SEM.   
Figure E4. Relationship between sputum AMP levels (A: LL-37, B: lysozyme, C: lactoferrin) 
and neutrophil elastase activity (Ns=73). Rho and p-value were obtained from Spearman rank 
correlation. 
Figure E5. A: ROC curve of sputum LL-37 for predicting severe exacerbation (Area under the 
curve (AUC) 0.76, 95% confidence interval (CI) 0.65-0.86, p<0.0001). B: ROC curve of sputum 
SLPI levels for predicting severe exacerbation (AUC 0.72, 95% CI 0.62-0.86, p<0.0001).  
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Figure E1:  
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Figure E2:  
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Figure E3: 
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Figure E4:  
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Figure E5: 
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